CASI Pharmaceuticals Inc (NASDAQ: CASI) stock closed at $5.20 on 11/20/23 after a major increase of 13.0%. The stock has risen 18.2% during the last week and has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
CASI is expected to continue to be a modest Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
CASI Pharmaceuticals has a current Value Trend Rating of C (Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. CASI Pharmaceuticals has a poor Appreciation Score of 16 but a very high Power Rating of 86, and the Neutral Value Trend Rating results.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment